Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Variants & evidence
645 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FLT3 D835I1 | ||||||||
| Gilteritinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID8351A 62-year-old female patient (AML5) was refractory to conventional chemotherapy and developed disease progression to quizartinib due to a D835I mutation. Using MTT to measure cytotoxicity, gilteritini… (full text at CIViC) PMID 27908881 · Lee et al., 2017 · Open in CIViC | civic |
| FLT3 D835 & I8361 | ||||||||
| FLT3/ABL/Aurora Kinase Inhibitor KW-2449 + Lestaurtinib + Quizartinib + SorafenibSubstitutes | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | B | Does Not Support Sensitivity Response | 3 | submitted | EID8925In this study, records of 69 FLT3 mutated AML patients treated with different FLT3 inhibitors were analyzed for emergence of new mutations. Before the start of therapy with a FLT3 inhibitor, 60 (87%) … (full text at CIViC) PMID 24737502 · Alvarado et al., 2014 · Open in CIViC | civic |
| FLT3 D835N1 | ||||||||
| (oncogenic) | Acute Myeloid LeukemiaCURATED_BROADER | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11091D835N was originally identified from an AML patient. Transfection of D835N into Ba/F3 cells led to IL3 independent growth, indicating an oncogenic driver effect for the variant in these cells. This ev… (full text at CIViC) PMID 28077790 · Nguyen et al., 2017 · Open in CIViC | civic |
| FLT3 D835 + FLT3 I8361 | ||||||||
| Gilteritinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID12622In a phase 3 trial comparing gilteritinib (120 mg/day) to salvage chemotherapy (SC) in adults with relapsed or refractory FLT3- mutated AML, patients were required to have FLT3 ITD or TKD (tyrosine ki… (full text at CIViC) PMID 31665578 · Perl et al., 2019 · Open in CIViC | civic |
| FLT3 D835V13 | ||||||||
| (diagnostic) | Acute Myeloid LeukemiaCURATED_BROADER | Diagnostic | B | Supports Positive | 3 | submitted | EID3011429 AML, 29 MDS, 36 ALL, 14 adult T-Cell leukemia, 17 malignant lymphoma, 10 CLL, 40 multiple myeloma, 11 CML and 3 essential thrombocytosis patients were analyzed for FLT3 gen mutation and FLT3 D835… (full text at CIViC) PMID 11290608 · Yamamoto et al., 2001 · Open in CIViC | civic |
| 〃 | Acute Myeloid LeukemiaCURATED_BROADER | Diagnostic | B | Supports Positive | 2 | submitted | EID3002The study is conducted with 144 AML patients. 6 of the normal karyotype patients with AML(n = 51), have FLT3 mutation. 2 of these mutations have been reported as D835V mutations.(%33 among FLT3 mutati… (full text at CIViC) PMID 26297285 · El Halabi et al., 2015 · Open in CIViC | civic |
| 〃 | Acute Myeloid LeukemiaCURATED_BROADER | |||||||
| FLT3 D835Y13 | ||||||||
| (oncogenic) | Acute Myeloid LeukemiaCURATED_BROADER | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID12617Cos7 cells transfected with mutant FLT3 D835Y cDNA demonstrated FLT3 ligand-independent tyrosine phosphorylation. 32D cells stably expressing mutant FLT3 D835Y proliferated without either IL-3 or reco… (full text at CIViC) PMID 11290608 · Yamamoto et al., 2001 · Open in CIViC | civic |
| 〃 | Acute Myeloid LeukemiaCURATED_BROADER | Oncogenic | D | Supports Oncogenicity | 2 | submitted | EID12812Ba/F3 cells expressing FLT3 D835Y were stably transfected, cultured for 48 hours and then cell viability was analyzed. Wild-type FLT3 cells grown with IL-3 or in the absence of IL-3 served as positive… (full text at CIViC) PMID 29372308 · Marhäll et al., 2018 · Open in CIViC | civic |
| 6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)-N-(4-(methylsulfonyl)phenyl)pyridin-2-amine | ||||||||
| FLT3 D839A1 | ||||||||
| Pexidartinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Resistance | 3 | submitted | EID8671Mutations were identified by in vitro saturation mutagenesis on the background of FLT3-ITD or FLT3-ITD/F691L. Proliferation and biochemical studies showed that the FLT3-ITD D839A (IC50 = 4.0μM) and FL… (full text at CIViC) PMID 25847190 · Smith et al., 2015 · Open in CIViC | civic |
| FLT3 D839G2 | ||||||||
| (prognostic) | Acute Promyelocytic Leukemia | Prognostic | C | Supports Poor Outcome | 1 | submitted | EID8908This is a case report about an adult patient with acute promyelocytic leukemia (APL) who had relapse in a testicle prior to systemic relapse of APL. Retrospective analysis of the preserved samples fro… (full text at CIViC) PMID 23816818 · Zou et al., 2013 · Open in CIViC | civic |
| (oncogenic) | Acute Myeloid LeukemiaCURATED_BROADER | Oncogenic | C | Supports Oncogenicity | 1 | submitted | EID8927Single strand polymorphism targeting FLT3 in addition to RUNX1, KIT, CEBPA, PTPN11, and NRAS was carried out to identify novel recurring gene mutations in an acute myeloid leukemia cohort comprised of… (full text at CIViC) PMID 15667533 · Smith et al., 2005 · Open in CIViC | civic |
| FLT3 D839H1 | ||||||||
| Pexidartinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Resistance | 2 | submitted | EID8673Mutations were identified by in vitro saturation mutagenesis on the background of FLT3-ITD. Proliferation studies showed that the FLT3-ITD D839H (IC50 = 8.6μM) confers relative resistance to PLX3397 i… (full text at CIViC) PMID 25847190 · Smith et al., 2015 · Open in CIViC | civic |
| FLT3 D839N1 | ||||||||
| Pexidartinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Resistance | 3 | submitted | EID8672Mutations were identified by in vitro saturation mutagenesis on the background of FLT3-ITD or FLT3-ITD/F691L. Proliferation and biochemical studies showed that the FLT3-ITD D839N (IC50 = 0.85μM) and F… (full text at CIViC) PMID 25847190 · Smith et al., 2015 · Open in CIViC | civic |
| FLT3 E573del1 | ||||||||
| Crenolanib + Lestaurtinib + Midostaurin + Ponatinib + Quizartinib + SorafenibSubstitutes | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID9307The construct supported IL-3 independent growth of Ba/F3 cells. It showed FLT-3 autophosphorylation and downstream signaling via STAT5, AKT, and ERK1/2 pathways. With IL-3 deprivation, the cells showe… (full text at CIViC) PMID 33914060 · Young et al., 2021 · Open in CIViC | civic |
| FLT3 E588_Y589INSKYFYVDFRE4 | ||||||||
| Palbociclib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | — | submitted | EID4738In an in vitro study, MOLM-14, PL21 and MV4-11 cell lines expressing FLT3 internal tandem duplication mutation (FLT3-ITD) demonstrated increased sensitivity to palbociclib treatment, compared to THP-1… (full text at CIViC) PMID 27099147 · Uras et al., 2016 · Open in CIViC | civic |
| Sunitinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID4735In a retrospective study of 15 acute myeloid leukemia patients, the patients with FLT3 internal tandem duplication mutation (n=2) were associated with improved response to sunitinib treatment. The pat… (full text at CIViC) PMID 15459012 · Fiedler et al., 2005 · Open in CIViC | civic |
| 〃 | Acute Myeloid LeukemiaCURATED_BROADER | |||||||
| FLT3 E611_F612INS252 | ||||||||
| Palbociclib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | — | submitted | EID4582In an in vitro study, MOLM-14, PL21 and MV4-11 cell lines expressing FLT3 internal tandem duplication mutation (FLT3-ITD) demonstrated increased sensitivity to palbociclib treatment, compared to THP-1… (full text at CIViC) PMID 27099147 · Uras et al., 2016 · Open in CIViC | civic |
| Sunitinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID4581In a retrospective study of 15 acute myeloid leukemia patients, the patients with FLT3 internal tandem duplication mutation (n=2) were associated with improved response to sunitinib treatment. The pat… (full text at CIViC) PMID 15459012 · Fiedler et al., 2005 · Open in CIViC | civic |
| FLT3 F691L8 | ||||||||
| Crenolanib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Resistance | 5 | submitted | EID12387FLT3 F691L was observed in 2 patient samples collected after at least 28 days of treatment with crenolanib. Prior to treatment with crenolanib, both patients were treated with quizartinib. Ba/F3 cells… (full text at CIViC) PMID 30651561 · Zhang et al., 2019 · Open in CIViC | civic |
| FLT3/ABL/Aurora Kinase Inhibitor KW-2449 | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Resistance | 3 | submitted | EID8846A screen using saturation mutagenesis of FLT3/ITD followed by selection of transfected TF1 cells in FLT3 TKIs identified F691L. Cytotoxicity assessed by MTT demonstrated Ba/F3 cells expressing FLT3/IT… (full text at CIViC) PMID 22858906 · Williams et al., 2013 · Open in CIViC | civic |
| Gilteritinib | Acute Myeloid Leukemia | |||||||
Data updated 21 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| Diagnostic |
| D |
| Supports Negative |
| 3 |
| submitted |
EID3031While all Balb/c mice received FLT3-ITD-Transduced cells, 10 developed a lethal hematopoietic disease with a median latency period of approximately 8-9 weeks. 40% of mice with FLT3-D835V-Transduced ce… (full text at CIViC) PMID 17690703 · Lu et al., 2007 · Open in CIViC |
| civic |
| AS602868 + Tyrphostin AG 1296Substitutes | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID3034Murine Ba/F3 cells with FLT3 D835V mutation were assessed as sensitive to both AS602868 and AG1296.(IC50 = 1.85uM and IC50 = 4.55uM, respectively) PMID 17330097 · Griessinger et al., 2007 · Open in CIViC | civic |
| Cytarabine + SunitinibCombination | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID3009SU11248 + Cytarabin has a synergic effect on Murine Ba/F3 cells with FLT3 D835V mutation (Combination Index = 0.59 for ED50, Combination Index = 0.71 for ED75, Combination Index = 0.82 for ED90) PMID 15304385 · Yee et al., 2004 · Open in CIViC | civic |
| Daunorubicin + SunitinibCombination | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID3010SU11248 + Daunorubicin has a synergic effect on Murine Ba/F3 cells with FLT3 D835V mutation. (Combination Index = 0.82 for ED50, Combination Index = 0.72 for ED75, Combination Index = 0.64 for ED90) PMID 15304385 · Yee et al., 2004 · Open in CIViC | civic |
| Gilteritinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID8518Ba/F3 cells were transfected to express FLT3-ITD or FLT3 tyrosine kinase domain mutations. Immunoblots revealed gilteritinib IC50s of 0.7nM, 1.6nM, and 5nM for D835H, FLT3-ITD, and wildtype (cell line… (full text at CIViC) PMID 27908881 · Lee et al., 2017 · Open in CIViC | civic |
| JQ-1 | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID3032JQ1 exerts significant lethal activity against Murine Ba/F3 cells with FLT3 D835V mutations (IC50 = 909nM) PMID 25053825 · Fiskus et al., 2014 · Open in CIViC | civic |
| Quizartinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Does Not Support Sensitivity Response | 4 | accepted | EID3012Murine Ba/F3 cell line has a restrictive sensitivity to Quizartinib (AC220), a second generation class II tyrosine kinase inhibitor (IC50 for proliferation = 172nM, IC50 for induction of apoptosis = 8… (full text at CIViC) PMID 23497317 · Kampa-Schittenhelm et al., 2013 · Open in CIViC | civic |
| Sunitinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | accepted | EID4022In a retrospective study of 15 acute myeloid leukemia patients, the patients with FLT3 D835 mutation (n=2) were associated with improved response to sunitinib treatment (2/2 vs. 2/7) compared to FLT3 … (full text at CIViC) PMID 15459012 · Fiedler et al., 2005 · Open in CIViC | civic |
| 〃 | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Does Not Support Sensitivity Response | 3 | accepted | EID3008Murine Ba/F3 cells with FLT3 D835V mutation were assessed as not sensitive to SU11248 (Sunitinib) with dose required to inhibit proliferation of cells to 50% of untreated controls ED50 = 110nM. PMID 15304385 · Yee et al., 2004 · Open in CIViC | civic |
| 〃 | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | — | submitted | EID4023In an in vitro study, Chinese hamster ovary cells transiently expressing FLT3 D835V mutation demonstrated sensitivity to sunitinib treatment (IC50: 30-300nM) similar to Chinese hamster ovary cells exp… (full text at CIViC) PMID 12531805 · O'Farrell et al., 2003 · Open in CIViC | civic |
| Tandutinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Resistance | 3 | accepted | EID3007Murine Ba/F3 cells with FLT3-D835V mutations were evaluated as non-responsive to MLN518 (Tandutinib). Cells with single FLT3 (D835V) mutants were resistant to MLN518(IC50 > 10uM) whereas cells with FL… (full text at CIViC) PMID 15256420 · Clark et al., 2004 · Open in CIViC | civic |
| Acute Myeloid LeukemiaCURATED_BROADER |
| Predictive |
| D |
| Supports Sensitivity Response |
| 3 |
| submitted |
EID12824Imidazo [1,2-a]pyridine derivative 6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)-N-(4-(methylsulfonyl)phenyl)pyridin-2-amine showed inhibitory effects on cell proliferation in MOLM14 cell… (full text at CIViC) PMID 38056299 · Wang et al., 2024 · Open in CIViC |
| civic |
| AG1295 + AGS324 + KW2449 + Linifanib + Ponatinib + Quizartinib + R406 + Sorafenib + SunitinibSubstitutes | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Does Not Support Sensitivity Response | 3 | accepted | EID11086A panel of 13 FLT3 tyrosine kinase inhibitors was tested against Ba/F3 cells transfected with FLT3 D835Y using MTT growth/survival assay, and results were compared to Ba/F3 cells transfected with FLT3… (full text at CIViC) PMID 28077790 · Nguyen et al., 2017 · Open in CIViC | civic |
| FLT3 Inhibitor FF-10101 Succinate | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID8111Second level inhibitor FF-10101 was used to measure the inhibition of FLT3 kinase activity due to the potential for patients with the D835Y mutation to have a relapse in AML after first-generation mon… (full text at CIViC) PMID 29187377 · Yamaura et al., 2018 · Open in CIViC | civic |
| Gilteritinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID12620A 60 year old female relapsed or refractory AML patient, white, and 55.2 kg, with favorable cytogenetic risk status Inv(16), and blast percentage of 95, had D835Y at time of bone marrow screening. Var… (full text at CIViC) PMID 32040554 · Tarver et al., 2020 · Open in CIViC | civic |
| 〃 | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID8108A 35 year-old male patient (AML4) presented with a FLT3-ITD mutation at diagnosis and was refractory to induction and salvage chemotherapy. He then received quizartinib and underwent allogenic transpl… (full text at CIViC) PMID 27908881 · Lee et al., 2017 · Open in CIViC | civic |
| Lestaurtinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID11095Ba/F3 cells with FLT3 D835Y were transplanted into mice. The cells were stably transfected with luciferase and this was used to monitor disease progression with luciferin injections to visualize biolu… (full text at CIViC) PMID 28077790 · Nguyen et al., 2017 · Open in CIViC | civic |
| Crenolanib + FLT3 Tyrosine Kinase Inhibitor TTT-3002 + Lestaurtinib + MidostaurinSubstitutes | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID11085A panel of 13 FLT3 tyrosine kinase inhibitors was tested against Ba/F3 cells transfected with FLT3 D835Y using MTT growth/survival assay, and results were compared to Ba/F3 cells transfected with FLT3… (full text at CIViC) PMID 28077790 · Nguyen et al., 2017 · Open in CIViC | civic |
| Sorafenib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID12625A patient (29/M) had 2 weeks with oral cavity ulcer and nasal bleeding and was diagnosed with AML with marrow including 91.5 % blasts with morphologic features of AML-M5. Karyotype was abnormal (47, … (full text at CIViC) PMID 27408351 · Yue et al., 2016 · Open in CIViC | civic |
| 〃 | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Does Not Support Sensitivity Response | 4 | submitted | EID11096Ba/F3 cells with FLT3 D835Y were transplanted into mice. The cells were stably transfected with luciferase and this was used to monitor disease progression with luciferin injections to visualize biolu… (full text at CIViC) PMID 28077790 · Nguyen et al., 2017 · Open in CIViC | civic |
| 〃 | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID12813Ba/F3 cells expressing FLT3 D835Y and treated with sorafenib demonstrated a dose-dependent inhibition of cell proliferation. Ba/F3 cells transformed with FLT3 D835Y showed a 50% inhibition of cell pro… (full text at CIViC) PMID 17229632 · Lierman et al., 2007 · Open in CIViC | civic |
| Tandutinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID12618MLN518 inhibited the proliferation of Ba/F3 cells transduced with FLT3 activation loop mutation D835Y (IC50 > 10 micromolar). In addition, MLN518 inhibited phosphorylation of FLT3, STAT5 and ERK. Trea… (full text at CIViC) PMID 15256420 · Clark et al., 2004 · Open in CIViC | civic |
| Predictive |
| C |
| Supports Sensitivity Response |
| — |
| submitted |
EID4736In a phase I study of 29 acute myeloid leukemia patients, patients with FLT3 internal tandem duplication (ITD) mutation (n=3) were associated with improved response to sunitinib monotherapy compared … (full text at CIViC) PMID 14654525 · O'Farrell et al., 2003 · Open in CIViC |
| civic |
| 〃 | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | — | submitted | EID4737In an in vitro study, leukemia M4;11 (endogenous), myeloid 32D (overexpression) and Chinese hamster ovary (transient expression) cell lines expressing FLT3 internal tandem duplication mutation demonst… (full text at CIViC) PMID 12531805 · O'Farrell et al., 2003 · Open in CIViC | civic |
| Predictive |
| D |
| Supports Resistance |
| 3 |
| submitted |
EID8562With Ba/F3 cells bearing FLT3-ITD F691L mutations and by in vitro proliferation assay, it was found that the cells exhibited >10-fold resistance to Gilteritinib. Similar resistance was found in cells … (full text at CIViC) PMID 32040554 · Tarver et al., 2020 · Open in CIViC |
| civic |
| Lestaurtinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Resistance | 3 | accepted | EID8341A screen using saturation mutagenesis of FLT3/ITD followed by selection of transfected TF1 cells in FLT3 TKIs identified F691L. Cytotoxicity assessed by MTT demonstrated Ba/F3 cells expressing FLT3/IT… (full text at CIViC) PMID 22858906 · Williams et al., 2013 · Open in CIViC | civic |
| Midostaurin | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Resistance | 3 | accepted | EID8342A screen using saturation mutagenesis of FLT3/ITD followed by selection of transfected TF1 cells in the FLT3 TKI midostaurin identified F691L in 1 of 400 clones. Cytotoxicity assessed by MTT demonstra… (full text at CIViC) PMID 22858906 · Williams et al., 2013 · Open in CIViC | civic |
| Pexidartinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID8674Deep sequencing revealed that no secondary F691L mutations were found in all 9 patients who achieved a partial or complete response on PLX3397 and who subsequently relapsed on the drug, suggesting thi… (full text at CIViC) PMID 25847190 · Smith et al., 2015 · Open in CIViC | civic |
| 〃 | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | B | Does Not Support Resistance | 1 | rejected | EID9716Overall response rate was 21% in this clinical trial with Pexidartinib on relapsed or refractory AML patients with FLT3-ITD. Forty two out of the total 80 patients were tested for FLT3 KD mutations be… (full text at CIViC) PMID 32330242 · Smith et al., 2020 · Open in CIViC | civic |
| 〃 | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | B | Does Not Support Resistance | 1 | submitted | EID9717Overall response rate was 21% in this clinical trial with Pexidartinib on relapsed or refractory AML patients with FLT3-ITD. Forty two out of the total 90 patients were tested for FLT3 KD mutations be… (full text at CIViC) PMID 32330242 · Smith et al., 2020 · Open in CIViC | civic |